Researchers find that SARS-CoV-2 spike protein persists in the skull-meninges-brain axis, driving neuroinflammation, ...

Researchers present a new therapeutic tool capable of inhibiting the proliferation of the SARS-CoV-2 virus that causes COVID-19. The results open up new perspectives in the fight against this ...

SARS-CoV-2 spike protein lingers in brain tissues for years. While vaccines cut accumulation by 50%, risks remain. Read more.

Explore groundbreaking research linking SARS-CoV-2 spike protein accumulation to long-lasting brain effects in long COVID.

The active ingredient in Kavigale is sipavibart, which is an immunoglobulin, antiviral monoclonal antibody that provides ...

SARS-CoV-2, the virus behind the Covid-19 pandemic, remains in the skull and meninges for years after infection, leading to a ...

The following is a summary of “COVID-19 vaccination and cerebral small vessel disease progression - A prospective cohort ...

Researchers at Karolinska Institutet have discovered how the SARS-CoV-2 virus, which causes COVID-19, manipulates human ...

LOUISE RAW speaks to Long Covid sufferer Sam Williams and others who feel let down by a state that ignores their debilitating ...

CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza ...

The lower chamber also called on the government to provide thermal scanners, infrared thermometers for temperature screening.